SWI Initiates Coverage on Cellular Biomedicine Group

SWI Initiates Coverage on
Cellular Biomedicine Group

 

Presents at the 8th Annual OneMedForum
7th Annual BioTech Showcase in San Francisco
Investing in the Immuno-Oncology Revolution

Wide World of Stocks Broadcast CEO Interview

 

 
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. CBMG is the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. CMBG’s cellular research and development comes from collaboration among scientists and doctors from the US, Europe and China. CMBG’s corporate business development strategy has two approaches: partnering our programs at the stage of early to mid-clinical development (i.e.: Knee Osteoarthritis, Cartilage Damage, Asthma), and licensing other applications after seeing them through the proof of concept stage.

 
Cellular Biomedicine Group brings together the world’s latest technology with industry-leading scientists and professors to research and develop safe treatments for those with serious conditions and diseases. CBMG is proud to have a share in an emerging field that has great potential for a significant positive impact on society. The company’s directors, scientists, doctors and employees share a sense of responsibility that ensures it maintains stringent international safety and quality control standards and focus on the patients and caregivers who will benefit the most from the application of breakthroughs in regenerative medicine.
Company Highlights

  • Robust product pipelines addressing multiple large market opportunities
  • Two products currently in clinical trials
  • Highly experienced executive and scientific team
  • GMP-certified facilities in the PRC designed to international, U.S. FDA standards, and Chinese regulatory bodies’ standards
  • The first cellular medicine company in China accredited with IS0 (International Standards Organization) 9001:2008 certification by internationally recognized quality management system SGS

Cellular Biomedicine Group was founded in 2009 as a specialty biomedicine company by a team of seasoned Chinese-American executives, scientists and doctors.  CBMG maintains offices in Palo Alto, California, in Hong Kong, and in Shanghai, Beijing and Wuxi, China.  In 2010 it established a research and development facility in Wuxi, China, and in 2012 it established an international-standard protocol-compliant manufacturing facility in Shanghai, China. CMBG’s focus has been to monetize the rapidly growing health care market in China by marketing and commercializing progenitor cell and immune cell therapeutics, related tools and products from our homegrown cell technology, as well as utilizing exclusively in-licensed intellectual properties.

CBMG is focused on developing and marketing safe and effective regenerative and cell-based therapies based on its cellular platforms, to treat serious injury and degenerative diseases including cancers, orthopedic diseases including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. CMBG has developed proprietary practical knowledge in the use of cell-based therapeutics that it believes could be used to help a great number of people suffering from cancer and serious chronic diseases. CMBG has two therapies undergoing clinical studies in China: stem cell based therapies to treat knee osteoarthritis (“KOA”) and an immune cell therapy to treat liver cancer (“HCC”). CMBG has initiated preclinical studies in Asthma, and Chronic Obstructive Pulmonary Disease (“COPD”) and clinical research studies in cartilage defect stem cell therapy.
In addition to standard protocols, CMBG uses proprietary processes and procedures for manufacturing our cell lines, comprised of:

  • Banking processes that ensure cell preservation and viability;
  • DNA identification for stem cell origin chain of custody; and
  • Bio-safety testing at independently certified laboratories